amphotora/E+ via Getty Images Introduction On May 29, I wrote an article titled "Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered." Since then, shares of the Abbott Laboratories (ABT) spin-off have returned roughly 30%, beating the S&P 500 by 23 points. Since becoming independent in April 2012, AbbVie Inc. (NYSE:ABBV) has returned 810%, beating both the S&P 500 and the healthcare ETF (XLV). Data by YCharts Although I'm obviously happy, my thesis has turned out to be correct, it's impor ...

More than 400 undergraduate and graduate students in the U.S. have benefited from the AbbVie Immunology Scholarship since its inception in 2016NORTH CHICAGO, Ill., Aug. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the 2024-2025 recipients of the AbbVie Immunology Scholarship, aimed to support students living with chronic, inflammatory diseases as they pursue higher education.Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/9253951-abbvie-immuno ...

SkinMedica®, by the makers of BOTOX® Cosmetic (onabotulinumtoxinA) launches the first and only product to use a proprietary complex of five forms of Hyaluronic Acid (HA) and Hydra Collagen, plus Advanced VITISENSCE® Technology for deeper hydrationIRVINE, Calif., Aug. 27, 2024 /PRNewswire/ -- For 25 years, SkinMedica® has been at the forefront of science-based skincare solutions, and today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of its next generation hydration product: Ski ...

These stocks are the A-team for income investors.Which income investors want to buy stocks with dividends likely to decline and iffy businesses? None. Instead, income investors want practically unstoppable dividend stocks.Three Motley Fool contributors think they've identified healthcare stocks that fit the bill. Here's why they picked Abbott Laboratories (ABT 0.53%), Amgen (AMGN 1.32%), and AbbVie (ABBV 0.60%).A Dividend King with a diverse business to buy and hold for yearsDavid Jagielski (Abbott Laborato ...

29 April 2024, Rhineland-Palatinate, Ludwigshafen: Photo: Uwe Anspach/dpa (Photo by Uwe ... [+] Anspach/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesWe believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock. MRK stock trades at 14x forward earnings, versus 20x for ABBV. We think this gap in valuation will narrow in favor of Merck in the coming years, given its superior revenue growth and profitability. There is more to the co ...

AbbVie (ABBV) and partner, Genmab (GMAB) , announced that the European Commission has granted conditional marketing authorization for the expanded use of Tepkinly (epcoritamab) to treat relapsed or refractory follicular lymphoma (FL) after two or more therapies. R/R FL is a particularly difficult-to-treat form of cancer, especially in later lines of therapy, for which there is currently no standard of care treatment.The encouraging regulatory update follows the positive opinion that was adopted by the advis ...

TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapyFL is an incurable form of non-Hodgkin's lymphoma (NHL), with about 13,000 estimated cases in Western Europe alone each year1NORTH CHICAGO, Ill., Aug. 19, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that ...

These stocks dividends continue to flow and grow.What do income investors like better than a stock that pays a juicy dividend yield? The answer is easy: A stock with a juicy dividend yield that's likely to grow its dividend payout over time.Such stocks aren't as hard to find as some might think. Here are three high-yield dividend stocks to buy now that have increased their dividends for 25 years or more.1. AbbVieAbbVie's (ABBV 0.26%) forward dividend yield of over 3.2% isn't as high as it was earlier this y ...

This list of top-selling drugs could look drastically different in a few years.You might think that if a drugmaker has a top-selling drug, it would be a lock to be a top-performing stock and a no-brainer buy. That may be true in some cases. In others, it can be a source of risk as investors grow concerned about what a company's growth opportunities will look like after the relevant patent expires, especially when the drug accounts for a significant chunk of the company's sales.The three top-selling drugs in ...

These stocks all pay more than 3%, and they have been regularly increasing their payouts in recent years.If you're a retiree looking to make the most of your nest egg, putting money into dividend stocks can be a great way to do that. You can help maximize the recurring income you earn by investing in dividend growth stocks, which have strong track records for raising their payouts. Dividend payments are never a guarantee, but companies with strong financials which prioritize growing their payouts can be ide ...